Main Topics

1. Etiology, pathogenesis, clinical features, points of convergence and differences in:
   1. Minimal cognitive impairment (MCI)
   2. Alzheimer’s Disease (AD) including non cognitive aspects
   3. Vascular dementia
   4. Cerebral amyloid angiopathy (CAA)
   5. Parkinson’s Disease (PD), PD dementia, atypical PD
   6. Non motor symptoms in PD
   7. Lewy body dementia (LBD)
   8. Frontotemporal dementia (FTD)
   9. Movement disorders other than PD (Tics, Restless Legs Syndrome, Dystonia)
   10. Depression and psychotic states in AD/PD
   11. Neurodevelopment and neurodegeneration
   12. Head injury
   13. Cognitive impairments in autoimmune disorders
   14. Amyotrophic lateral sclerosis (ALS)
   15. Multiple systems atrophy
2. Genetics of AD and PD
3. Neurogenetics of AD, PD, FTD; Genetic basis for responsiveness to treatments and pharmacogenomics
4. Epidemiology and pharmacoeconomics, economic aspects, quality of life in dementia and PD
5. Biomarkers, peripheral markers, diagnostics and genetic aspects of neurodegenerative diseases
6. Neuroimaging - its role in early diagnosis, disease progression and evaluation of clinical trials in MCI, AD, PD, Lewy body dementia and related neurodegenerative disorders
7. Leading and new hypotheses on neurodegeneration, major risk factors, CNS-periphery communication in AD and PD, environmentally induced risks and culprits in neurodegenerative diseases such as AD, PD, Lewy body dementia, CAA, FTD
8. Physiological and pathological role of β-amyloid, β-amyloid oligomers, intracellular and extracellular β-amyloid, its precursors, β-amyloid modulation and removal; Biology of APP and secretases
9. Tau and mechanistic aspects
10. Energy metabolism, β-amyloid / tau pathology, oxidative stress, apolipoprotein-E, axonal transport and others; Inflammation and apoptosis; Mechanistic aspects in neurodegeneration
11. Tauopathies and synucleopathies; Interaction between tau, β- amyloid and α-synuclein
12. AD, PD, Lewy body dementia, FTD and related neurodegenerative diseases: Animal models
13. Potential disease modification in AD (α-, β-, γ- secretases as targets; β- amyloid degradation, prevention of β- amyloid aggregation)
14. Treatment and potential diseases modification in AD, CAA, Lewy body dementia and related diseases (direct and receptor-mediated modulation of kinases involved in etiopathogenesis)
15. Cholinergic and glutamatergic treatments in neurodegenerative diseases (other potential transmitters?); Drug interaction
16. Role of cholesterol and lipids in β- amyloid modulation – basic and therapeutic aspects in AD
17. Low molecular weight glycosaminoglycans (GAG), GAG-mimetics and β-sheet breakers in the treatment of neurodegenerative disorders
18. Immunotherapies and related strategies in AD, CAA and PD related diseases
19. Mechanism and treatment strategies in PD, PD dementia and atypical PD
20. Treatment of motor and non motor symptoms and complications in PD
21. Dopamine and serotonergic treatments in PD and related disorders
22. Lewy body dementia: Basic and therapeutic strategies (e.g. prevention of α-synuclein aggregation)
23. α-Synuclein and the proteosome system in PD and related disorders
24. Stem cells, gene therapies, new drug delivery systems: patches, pumps, duodenal applications, transplantation of cell systems; surgical strategies and others in neurodegenerative diseases
25. Latest important findings